Cliff Asness’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-18,720
Closed -$1.27M 2334
2022
Q3
$1.27M Buy
+18,720
New +$1.03M ﹤0.01% 1412
2022
Q1
Sell
-7,091
Closed -$208K 2329
2021
Q4
$208K Buy
+7,091
New +$220K ﹤0.01% 2081
2021
Q3
Sell
-13,080
Closed -$428K 2372
2021
Q2
$428K Buy
13,080
+7,396
+130% +$289K ﹤0.01% 1952
2021
Q1
$232K Sell
5,684
-629
-10% -$28.9K ﹤0.01% 2074
2020
Q4
$271K Buy
6,313
+339
+6% +$16.7K ﹤0.01% 2001
2020
Q3
$326K Sell
5,974
-29,370
-83% -$1.87M ﹤0.01% 1884
2020
Q2
$2.23M Sell
35,344
-3,255
-8% -$223K ﹤0.01% 1111
2020
Q1
$1.97M Buy
38,599
+18,596
+93% +$1.25M ﹤0.01% 1080
2019
Q4
$1.59M Buy
20,003
+4,360
+28% +$258K ﹤0.01% 1354
2019
Q3
$759K Buy
15,643
+3,836
+32% +$200K ﹤0.01% 1609
2019
Q2
$621K Buy
+11,807
New +$679K ﹤0.01% 1661
2019
Q1
Sell
-8,390
Closed -$344K 2247
2018
Q4
$344K Sell
8,390
-11,416
-58% -$428K ﹤0.01% 1918
2018
Q3
$753K Buy
19,806
+698
+4% +$30.9K ﹤0.01% 1812
2018
Q2
$864K Sell
19,108
-7,855
-29% -$358K ﹤0.01% 1778
2018
Q1
$1.3M Buy
26,963
+5,487
+26% +$306K ﹤0.01% 1560
2017
Q4
$845K Buy
21,476
+4,362
+25% +$163K ﹤0.01% 1731
2017
Q3
$531K Buy
17,114
+2,791
+19% +$78.5K ﹤0.01% 1919
2017
Q2
$392K Buy
14,323
+8,881
+163% +$264K ﹤0.01% 1971
2017
Q1
$201K Buy
+5,442
New +$137K ﹤0.01% 2113

Other funds holding GBT

Cliff Asness's GBT Position: Q4 2022 in Review

Cliff Asness sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 18,720 shares — an estimated $1.27M sold.

Cliff Asness first reported a position in GBT in Q1 2017 and held it in 19 quarters. The position peaked at $2.23M in Q2 2020. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Cliff Asness reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Cliff Asness sold 18,720 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $1.27M.
  • Cliff Asness first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 19 quarters.
  • Cliff Asness's Global Blood Therapeutics, Inc. position peaked at $2.23M in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.